Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01890109 · ClinicalTrials.gov registry record · Phase 1
Study of Erenumab (AMG 334) in Women With Hot Flashes
A Phase 1 study, sponsored by Amgen.
- Completed
- Registry status
- Phase 1
- Development phase
- 103
- Enrollment target
NCT01890109 is a Phase 1 study that has completed, run by Amgen. The registered enrollment target is 103 participants.
The verdict
NCT01890109, a Phase 1 study, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 103 participants
- Enrollment target
Study Summary
The primary objective of this study was to evaluate the frequency of moderate to severe daily hot flashes 4 weeks after a single dose of erenumab (AMG 334) in women with hot flashes associated with menopause.
Interventions
- DRUG Placebo
- BIOLOGICAL Erenumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 103 participants |
| Start Date | 2013-05-13 |
| Est. Completion | 2014-03-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01890109
The ClinicalTrials.gov registry entry for NCT01890109 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 103 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01890109 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01890109 about?
NCT01890109 is a clinical study titled "Study of Erenumab (AMG 334) in Women With Hot Flashes". The primary objective of this study was to evaluate the frequency of moderate to severe daily hot flashes 4 weeks after a single dose of erenumab (AMG 334) in women with hot flashes associated with menopause.
What is the current status of trial NCT01890109?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 103 participants. The study started on 2013-05-13. Estimated completion is 2014-03-11.
What interventions are being tested in trial NCT01890109?
The interventions under investigation include: Placebo (DRUG), Erenumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT01890109?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.